Experienced in Hemolytic-Uremic Syndrome

Dr. Erin R. Alesi

Hematology Oncology | Hematology | Oncology
Mcv Associated Physicians
1001 E Leigh St, 
Richmond, VA 
Accepting New Patients
Offers Telehealth
Experienced in Hemolytic-Uremic Syndrome
Mcv Associated Physicians
1001 E Leigh St, 
Richmond, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Erin Alesi is a Hematologist Oncology specialist and a Hematologist in Richmond, Virginia. Dr. Alesi is rated as an Experienced provider by MediFind in the treatment of Hemolytic-Uremic Syndrome. Her top areas of expertise are Laryngeal Cancer, Lung Cancer, Small Cell Lung Cancer (SCLC), Gastrostomy, and Bone Marrow Aspiration. Dr. Alesi is currently accepting new patients.

Her clinical research consists of co-authoring 12 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in VA
Hospital Affiliations
Community Memorial Hospital
Medical College Of Virginia Hospitals
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

MCV ASSOCIATED PHYSICIANS
1001 E Leigh St, Richmond, VA 23298

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Suspended
Publish Date: October 10, 2025
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
An Open-Label, Phase III Study of Platinum-Gemcitabine With or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
An Open-Label, Phase III Study of Platinum-Gemcitabine With or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Enrollment Status: Terminated
Publish Date: October 03, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Carboplatin, Cisplatin, Gemcitabine, Nivolumab
Study Phase: Phase 3
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cabozantinib S-malate, Docetaxel, Gemcitabine Hydrochloride, Nab-paclitaxel, Nivolumab, Paclitaxel, Ramucirumab
Study Phase: Phase 2
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients
Enrollment Status: Active_not_recruiting
Publish Date: August 22, 2025
Intervention Type: Biological
Study Drug: Aglatimagene besadenovec
Study Phase: Phase 2
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Other, Drug
Study Drugs: Pembrolizumab, Pemetrexed, Carboplatin
Study Phase: Phase 2
View 8 Less Clinical Trials

12 Total Publications

Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial.
Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 22, 2024
Similar Doctors
Advanced in Hemolytic-Uremic Syndrome
Dr. John C. Barrett
Hematology | Oncology
Advanced in Hemolytic-Uremic Syndrome
Dr. John C. Barrett
Hematology | Oncology

Mcv Associated Physicians

1001 E Leigh St, 
Richmond, VA 
 (0.1 miles away)
804-828-7929
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Barrett is a Hematologist and an Oncologist in Richmond, Virginia. Dr. Barrett is rated as a Distinguished provider by MediFind in the treatment of Hemolytic-Uremic Syndrome. His top areas of expertise are Hemophilia A, Hemophilia B, Hemophilic Arthropathy, Philadelphia-Negative Chronic Myeloid Leukemia, and Bone Marrow Aspiration. Dr. Barrett is currently accepting new patients.

Advanced in Hemolytic-Uremic Syndrome
Dr. Shejal B. Patel
Hematology Oncology | Palliative Medicine | Hematology
Advanced in Hemolytic-Uremic Syndrome
Dr. Shejal B. Patel
Hematology Oncology | Palliative Medicine | Hematology

Mcv Associated Physicians

1300 E Marshall St, 
Richmond, VA 
 (2.0 miles away)
804-828-0450
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Shejal Patel is a Hematologist Oncology specialist and a Palliative Medicine provider in Richmond, Virginia. Dr. Patel is rated as a Distinguished provider by MediFind in the treatment of Hemolytic-Uremic Syndrome. Her top areas of expertise are Multiple Myeloma, Thrombocytopenia, Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), and Bone Marrow Aspiration. Dr. Patel is currently accepting new patients.

Advanced in Hemolytic-Uremic Syndrome
Dr. Sosipatros A. Boikos
Hematology Oncology | Hematology | Oncology
Advanced in Hemolytic-Uremic Syndrome
Dr. Sosipatros A. Boikos
Hematology Oncology | Hematology | Oncology
1250 E Marshall St, Internal Medicine, 
Richmond, VA 
 (1.9 miles away)
804-828-7999
Languages Spoken:
English, Greek
See accepted insurances
Accepting New Patients

Sosipatros Boikos is a Hematologist Oncology specialist and a Hematologist in Richmond, Virginia. Dr. Boikos is rated as a Distinguished provider by MediFind in the treatment of Hemolytic-Uremic Syndrome. His top areas of expertise are Synovial Sarcoma, Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Neuroendocrine Tumor, and Bone Marrow Aspiration. Dr. Boikos is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Alesi's expertise for a condition
ConditionClose
    View All 15 Advanced Conditions
    View All 76 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile